First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 1, 2009, Pages 131-140

  Sankaranarayanan, Sethu ^a   Holahan, Marie A ^a   Colussi, Dennis ^a   Crouthamel, Ming Chih ^a   Devanarayan, Viswanath ^a   Ellis, Joan ^a   Espeseth, Amy ^a   Gates, Adam T ^a   Graham, Samuel L ^a   Gregro, Allison R ^a   Hazuda, Daria ^a   Hochman, Jerome H ^a   Holloway, Katharine ^a   Jin, Lixia ^a   Kahana, Jason ^a   Lai, Ming Tain ^a   Lineberger, Janet ^a   McGaughey, Georgia ^a   Moore, Keith P ^a   Nantermet, Philippe ^a   Pietrak, Beth ^a   Price, Eric A ^a   Rajapakse, Hemaka ^a   Stauffer, Shaun ^a   Steinbeiser, Melissa A ^a   Seabrook, Guy ^a   Selnick, Harold G ^a   Shi, Xiao Ping ^a   Stanton, Matthew G ^a   Swestock, John ^a   Tugusheva, Katherine ^a   Tyler, Keala X ^a   Vacca, Joseph P ^a   Wong, Jacky ^a   Wu, Guoxin ^a   Xu, Min ^a   Cook, Jacquelynn J ^a   Simon, Adam J ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; CATHEPSIN D; CYTOCHROME P450 3A4; GLYCOPROTEIN P; N [4 [5 (1 AMINO 1 METHYL 2 PHENYLETHYL) 1,3,4 OXADIAZOL 2 YL] 3 CHLORO 6 [(2 METHOXYETHYL) 2 METHYLCYCLOPROPYL]METHYL]AMINO]PYRIDIN 2 YL] N METHYLMETHANESULFONAMIDE]; RENIN; RITONAVIR; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; ENZYME INHIBITOR; SECRETASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TRANSPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; IC 50; IN VITRO STUDY; LOW DRUG DOSE; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN SECRETION; RHESUS MONKEY; ANIMAL; CEREBROSPINAL FLUID; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MACACA; TRANSGENIC MOUSE;

AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; ENZYME INHIBITORS; HUMANS; INFUSIONS, INTRAVENOUS; MACACA MULATTA; MICE; MICE, TRANSGENIC; P-GLYCOPROTEIN; TRANSFECTION;

EID: 59149083352     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.143628     Document Type: Article

References (52)

1. Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabó B, Hashimoto Y, Maruyama K, Tanuma S, Kiso Y, et al. (2006) The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 96:533-540.
2. Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, et al. (2005) Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 312:635-643.
3. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, and Holtzman DM (2006) Human amyloid-beta synthesis and clearance rates as measured in cere-brospinal fluid in vivo. Nat Med 12:856-861.
4. Best JD, Jay MT, Otu F, Ma J, Nadin A, Ellis S, Lewis HD, Pattison C, Reilly M, Harrison T, et al. (2005) Quantitative measurement of changes in amyloid- beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5- difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6, 7-dihydro-5H-dibenzo[b,d]azepin-7- yl]-L-alaninamide]. J Pharmacol Exp Ther 313:902-908.
5. Blennow K, de Leon MJ, and Zetterberg H (2006) Alzheimer's disease. Lancet 368:387-403.
6. Booth-Genthe CL, Louie SW, Carlini EJ, Li B, Leake BF, Eisenhandler R, Hochman JH, Mei Q, Kim RB, Rushmore TH, et al. (2006) Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse. J Pharmacol Toxicol Methods 54:78-89.
7. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, and Wong PC (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4:233-234.
8. Chang WP, Koelsch G, Wong S, Downs D, Da H, Weerasena V, Gordon B, Devasam- udram T, Bilcer G, Ghosh AK, et al. (2004) In vivo inhibition of A beta production by memapsin 2 (beta-secretase) inhibitors. J Neurochem 89:1409 -1416.
9. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, et al. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 23:8844-8853.
10. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, et al. (2005) Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 280:30797-30806.
11. Goate A (2006) Segregation of a missense mutation in the amyloid beta-protein precursor gene with familial Alzheimer's disease. J Alzheimers Dis 9:341-347.
12. Ghosh AK, Bilcer G, Hong L, Koelsch G, and Tang J (2007) Memapsin 2 (beta-secretase) inhibitor drug, between fantasy and reality. Curr Alzheimer Res 4:418 -422.
13. Gilberto DB, Zeoli AH, Szczerba PJ, Gehret JR, Holahan MA, Sitko GR, Johnson CA, Cook JJ, and Motzel SL (2003) An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys. Contemp Top Lab Anim Sci 42:53-59.
14. Hardy J and Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
15. Harrison SM, Harper AJ, Hawkins J, Duddy G, Grau E, Pugh PL, Winter PH, Shilliam CS, Hughes ZA, Dawson LA, et al. (2003) BACE1 (beta-secretase) trans-genic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol Cell Neurosci 24:646 -655.
16. Hitchcock SA and Pennington LD (2006) Structure-brain exposure relationships. J Med Chem 49:7559 -7583.
17. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, and Tang J (2000) Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290:150 -153.
18. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, and Yan R (2006) Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9:1520 -1525.
19. Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, et al. (2007) Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem 100:802-809.
20. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, and Beyreuther K (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271:22908-22914.
21. Kim KS, Miller DL, Sapienza VJ, Chen CJ, Bai C, Grundke-Iqbal I, Currie JR, and Wisniewski HM (1988) Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun 2:121-130.
22. Kojro E and Fahrenholz F (2005) The non-amyloidogenic pathway: structure and function of alpha-secretases. Subcell Biochem 38:105-127.
23. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, et al. (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25:11693-11709.
24. Lamb BT, Sisodia SS, Lawler AM, Slunt HH, Kitt CA, Kearns WG, Pearson PL, Price DL, and Gearhart JD (1993) Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice. Nat Genet 5:22-30.
25. Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KE, Finley JE, et al. (2006) Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 319:924-933.
26. Lin JH (2008) CSF as a surrogate for assessing CNS exposure: An industrial perspective. Curr Drug Metab 9:46 -59.
27. Lindsley SR, Moore KP, Rajapakse HA, Selnick HG, Young MB, Zhu H, Munshi S, Kuo L, McGaughey GB, Colussi D, et al. (2007) Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett 17: 4057-4061.
28. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, et al. (2001) Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4:231-232.
29. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, and Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037.
30. Moore KP, Zhu H, Rajapakse HA, McGaughey GB, Colussi D, Price EA, Sankara-narayanan S, Simon AJ, Pudvah NT, Hochman JH, et al. (2007) Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett 17:5831-5835.
31. Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, et al. (2006) BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J Neurochem 99:1555-1563.
32. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, and Disterhoft JF (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41:27-33.
33. Pietrak BL, Crouthamel MC, Tugusheva K, Lineberger JE, Xu M, DiMuzio JM, Steele T, Espeseth AS, Stachel SJ, Coburn CA, et al. (2005) Biochemical and cell-based assays for characterization of BACE-1 inhibitors. Anal Biochem 342:144-151.
34. Rajapakse HA, Nantermet PG, Selnick HG, Munshi S, McGaughey GB, Lindsley SR, Young MB, Lai MT, Espeseth AS, Shi XP, et al. (2006) Discovery of oxadiazole tertiary carbinamine inhibitors of beta-secretase (BACE-1). J Med Chem 49:7270-7273.
35. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freed- man SB, Frigon NL, Games D, HuK, et al. (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10:1317-1324.
36. Roberson ED and Mucke L (2006) 100 years and counting: prospects for defeating Alzheimer's disease. Science 314:781-784.
37. Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Shi XP, Tugusheva K, Tyler KX, Kahana J, Ellis J, Jin L, et al. (2008) In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol ExpTher324:957- 969.
38. Scheff SW and Price DA (2006) Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis 9:101-115.
39. Shi XP, Tugusheva K, Bruce JE, Lucka A, Chen-Dodson E, Hu B, Wu GX, Price E, Register RB, Lineberger J, et al. (2005) Novel mutations introduced at the beta- site of amyloid beta protein precursor enhance the production of amyloid beta peptide by BACE1 in vitro and in cells. J Alzheimers Dis 7:139-148.
40. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, and May PC (2007) Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 30:317-325.
41. Stachel SJ, Coburn CA, Sankaranarayanan S, Price EA, Wu G, Crouthamel M, Pietrak BL, Huang Q, Lineberger J, Espeseth AS, et al. (2006) Macrocyclic inhibitors of beta-secretase: functional activity in an animal model. J Med Chem 49:6147-6150.
42. Stanton MG, Stauffer SR, Gregro AR, Steinbeiser M, Nantermet P, Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Ellis J, et al. (2007) Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of beta- amyloid. J Med Chem 50:3431-3433.
43. Stauffer SR, Stanton MG, Gregro AR, Steinbeiser MA, Shaffer JR, Nantermet PG, Barrow JC, Rittle KE, Collusi D, Espeseth AS, et al. (2007) Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind beta-secretase in a N-terminal 10s- loop down conformation. Bioorg Med Chem Lett 17:1788-1792.
44. Steiner H, Capell A, Leimer U, and Haass C (1999) Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 249:266-270.
45. Trojanowski JQ, Shin RW, Schmidt ML, and Lee VM (1995) Relationship between plaques, tangles, and dystrophic processes in Alzheimer's disease. Neurobiol Aging 16:335-340; discussion 341-345.
46. Vassar R (2005) Beta-secretase, APP and Abeta in Alzheimer's disease. Subcell Biochem 38:79-103.
47. Van Nostrand WE, Wagner SL, Shankle WR, Farrow JS, Dick M, Rozemuller JM, Kuiper MA, Wolters EC, Zimmerman J, and Cotman CW (1992) Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci U S A 89:2551-2555.
48. WangGT, ChungCC, Holzman TF, and Krafft GA(1993) A continuous fluorescence assay of renin activity. Anal Biochem 210:351-359.
49. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, and Haass C (2006) Control of peripheral nerve myelination by the β-secretase BACE1. Science 314:664-666.
50. Xu RN, Fan L, Rieser MJ, and El-Shourbagy TA (2007) Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS. J Pharm Biomed Anal 44:342-355.
51. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, and Lin JH (2001) In vitro substrate identification studies for P-glycoprotein- mediated transport: Species difference and predictability of in vivo results. J Pharmacol Exp Ther 296:723-735.
52. Zeldin RK and Petruschke RA (2004) Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimi- crob Chemother 53:4-9.